

<b>1.</b>	<b><u>CLINICAL EVALUATION</u></b>	<b>1</b>
<b>1.1.</b>	<b>Introduction.....</b>	<b>1</b>
<b>1.2.</b>	<b>Clinical Evaluation - Definitions .....</b>	<b>3</b>
<b>1.3.</b>	<b>History of Clinical Evaluation within the EU Regulatory System for Medical Devices.....</b>	<b>5</b>
<b>1.4.</b>	<b>The Legal Basis for Clinical Evaluation within the MDR.....</b>	<b>9</b>
1.4.1.	Compliance with the General Safety and Performance Requirements .....	9
1.4.2.	The Core Legal Elements for Clinical Evaluation .....	10
1.4.2.1.	Summary of Tasks for the Clinical Evaluation out of the Core Legal Requirements .....	17
1.4.3.	Other Legal Requirements for Clinical Evaluation within the MDR.....	19
1.4.3.1.	Clinical Evaluation as a Manufacturer’s Obligation under the QMS (Art. 10).....	19
1.4.3.2.	Technical Documentation (Annexes II and III).....	19
1.4.3.3.	Conformity Assessment.....	20
1.4.3.4.	Requirements for NBs .....	20
1.4.3.5.	Market Surveillance.....	22
1.4.3.6.	Post-Market Surveillance (PMS).....	23
1.4.3.7.	Exemptions to the Need of Clinical Data.....	24
1.4.3.8.	Use of Clinical Data of an Equivalent Medical Device .....	25
1.4.3.9.	Scientific Advice, according to MDR.....	26
1.4.3.10.	Summary of Safety and Clinical Performance (SSCP).....	27
1.4.3.11.	Clinical Evaluation of Annex XVI Products.....	27
1.4.3.12.	Qualifications and Selection of Clinical Evaluators .....	29
<b>1.5.</b>	<b>Clinical Benefit/Risk Determination and the Clinical Evaluation Process - Overview.....</b>	<b>30</b>
1.5.1.	Clinical Benefit/Risk Determination .....	30
1.5.2.	Clinical Evaluation Process – Short Survey on Steps .....	33
<b>1.6.</b>	<b>Steps of the Clinical Evaluation Process .....</b>	<b>36</b>
1.6.1.	Stage 0: Scoping and Clinical Evaluation Plan .....	36
1.6.1.1.	Essential Elements of Clinical Evaluation Planning .....	38
1.6.1.1.1.	Parts of the Clinical Evaluation Plan .....	38

1.6.1.1.2.	A Clear Description of the MD .....	39
1.6.1.1.3.	General Safety and Performance Requirements (GSPR) to be Demonstrated by Clinical Evaluation .....	41
1.6.1.1.4.	The Clearly Specified Intended Purpose .....	43
1.6.1.1.5.	Determining the Specific Need for Clinical Data .....	46
1.6.1.1.6.	Intended Target Groups, Indications, Contraindications.....	48
1.6.1.1.7.	Intended Clinical Benefits .....	48
1.6.1.1.8.	Aspects of Clinical Safety .....	51
1.6.1.1.9.	Parameters to Address Acceptability of B/R-R Against the State of the Art .....	54
1.6.1.1.10.	Device Specific Guidances, Common Specifications.....	55
1.6.1.1.11.	Clinical Aspects of Specific Components .....	55
1.6.1.1.12.	Clinical Development Plan .....	55
1.6.1.2.	Specific Aspects of Clinical Evaluation Planning .....	57
1.6.1.2.1.	Demonstration of Equivalence .....	57
1.6.1.2.2.	Well Established Technologies .....	63
1.6.1.2.3.	Unmet Clinical Needs.....	64
1.6.1.2.4.	Breakthrough Devices.....	65
1.6.1.3.	Diagnostic Algorithms Implemented in Software; Clinical Evaluation of SaMD and MDSW .....	66
1.6.2.	Stage 1: Identification and Generation of Pertinent Data.....	69
1.6.2.1.	Introduction .....	69
1.6.3.	Stage 2: Appraisal of Pertinent Data.....	83
1.6.3.1.	Tasks of Appraisal .....	83
1.6.4.	Stage 3: Analysis of the Clinical Data .....	87
1.6.4.1.	The Main Tasks and Conclusions to be Achieved by the Analysis Step 3 .....	88
1.6.4.2.	Four Methodological Topics of Analysis .....	89
1.6.4.3.	Analysis of Benefit-Risk Determination of the MD/Equivalent MD and of the State of the Art in the Medical Field Concerned .....	91
1.6.4.4.	Definitions to be Recalled here for Analysis.....	91
1.6.4.5.	Evaluation of the Description of the Intended Purpose of the Device .....	93

1.6.4.6.	Evaluation and Quantification of the Device`s Benefit to the Patient.....	94
1.6.4.7.	Evaluation of the Clinical Risks of Devices.....	96
1.6.4.8.	Evaluation of Acceptability of the Benefit/Risk Profile .....	97
1.6.5.	Stage 4: The Clinical Evaluation Report (CER) .....	100
1.6.5.1.	Some Practically Important Topics.....	100
1.6.5.2.	Structure of the Clinical Evaluation Report.....	101
1.6.5.3.	Proposal for Possible Structure and Content of a CER.....	111
1.6.6.	Stage 5: Post Market Clinical Follow Up (PMCF).....	114
1.6.6.1.	Scope and Role of PMCF in MDR.....	114
1.6.6.2.	Main Sources for PMCF in MDR .....	115
1.6.6.2.1.	PMCF as seen under the Clinical Evaluation Process .....	115
1.6.6.2.2.	PMCF as seen in Relation to the Post Market Surveillance System (PMS) .....	117
1.6.6.3.	The PMCF Plan.....	117
1.6.6.4.	PMCF Evaluation Reports (MDR: Annex XIV.B.7 and 8) .....	121
1.6.6.5.	Main Documents PMCF-Information has to be included in addition to the CER are.....	122
1.6.6.5.1.	Periodic Safety Update Report (PSUR) for Risk Class II and III Devices.....	122
1.6.6.5.2.	Summary of Safety and Clinical Performance (SSCP).....	123
1.6.6.5.3.	Post Market Surveillance Report (PMS Report) for Risk Class I Devices.....	125
1.6.6.5.4.	PMS Plan.....	125
1.6.6.5.5.	The Clinical Evaluation Plan and its Updates.....	128
1.6.6.5.6.	IFU, Promotional Material and other Relevant Statements and Claims of the Manufacturer .....	129

**2. SYSTEMATIC SEARCHING FOR LITERATURE ON CLINICAL (STATE OF THE ART) EVIDENCE OF MEDICAL DEVICES** **129**

<b>2.1.</b>	<b>Checklist to Support Efficient Information Retrieval on Medical Devices Evidence.....</b>	<b>130</b>
2.1.1.	Description and Technical Characteristics of the Technology .....	130

2.1.1.1.	Characteristics of the Technology .....	130
2.1.1.2.	Regulatory status of the technology.....	131
2.1.1.3.	Health Problem and Current Clinical Practice .....	132
2.1.1.3.1.	Summary of Issues Relating to the Health Problem and Current Clinical Practice.....	132
2.1.1.3.2.	Overview of the Disease or Health Condition .....	132
2.1.1.3.3.	Target Population .....	133
2.1.1.3.4.	Clinical Management of the Disease or Health Condition .....	133
2.1.1.3.5.	Comparators in the Assessment.....	134
2.1.1.4.	Current Use of the Technology.....	134
2.1.1.4.1.	Summary of Issues Relating to Current Use of the Technology.....	134
2.1.1.4.2.	Current Use of the Technology (experience and scale).....	134
2.1.1.4.3.	Reimbursement and Assessment Status of the Technology (if known) .....	135
2.1.1.5.	Investments and Tools Required .....	135
2.1.1.5.1.	Requirements to Use the Technology .....	136
2.1.1.5.2.	Procedures Required to Use the Technology .....	136
2.1.1.5.3.	Investments, Disinvestments and Changes in Service Organisation.....	137
2.1.1.6.	Clinical Effectiveness and Safety.....	137
<b>2.2.</b>	<b>Planning a Search Using the PICO framework .....</b>	<b>138</b>
<b>2.3.</b>	<b>Developing a Literature Search Protocol (according to MEDDEV 2.7/1 rev 4, A5.3.) .....</b>	<b>139</b>
<b>2.4.</b>	<b>Scientific (medical) Databases for Retrieving Clinical Evidence: An Overview .....</b>	<b>141</b>
2.4.1.	Introduction to Medline and PubMed.....	141
2.4.1.1.	Medline.....	141
2.4.1.2.	PubMed.....	141
2.4.1.2.1.	How to Access PubMed .....	142
2.4.1.3.	Planning a Search in PubMed .....	142
2.4.1.3.1.	Consider the Topic and Appropriate Search Terms (according to PICO) .....	143
2.4.1.3.2.	Write a Search Plan.....	143

2.4.1.4.	Additional Features .....	146
2.4.1.4.1.	Automatic Mapping and the MeSH Database.....	146
2.4.1.5.	The MeSH Database .....	147
2.4.1.6.	Clinical Queries .....	148
2.4.2.	Introduction to Embase (via Elsevier) .....	151
2.4.2.1.	Using the Dedicated Embase Medical Devices Search Form .....	151
2.4.2.2.	Planning a Search Using the PICO Framework.....	156
2.4.2.3.	Browsing Emtree .....	157
2.4.2.4.	Using the Dedicated Embase PICO Search Form to Retrieve Clinical Device Evidence .....	158
2.4.2.5.	Results Management (Emailing and Exporting References).....	159
2.4.3.	Searching the Cochrane Library .....	160
2.4.3.1.	What is the Cochrane Library? .....	160
2.4.3.2.	The Databases .....	161
2.4.3.3.	When to Use the Cochrane Library .....	162
2.4.3.4.	Accessing the Cochrane Library.....	162
<b>2.5.</b>	<b>Efficient Search Strategies for Identifying Clinical Trials on Medical Devices .....</b>	<b>163</b>
2.5.1.	Trial databases.....	164
2.5.1.1.	ClinicalTrials.gov .....	164
2.5.1.2.	WHO ICTRP (International Clinical Trials Registry Platform).....	165
2.5.1.3.	EU Clinical Trials Register .....	165
2.5.2.	Searching Clinical Trials Databases.....	165
<b>2.6.</b>	<b>The Literature Search Report.....</b>	<b>166</b>
2.6.1.	A Possible Format for the Literature Search Report:.....	167

### **3. CLINICAL INVESTIGATIONS WITHIN THE CONTEXT OF THE MDR**

**170**

<b>3.1.</b>	<b>Sources.....</b>	<b>170</b>
<b>3.2.</b>	<b>Definitions .....</b>	<b>171</b>

<b>3.3.</b>	<b>OVERALL ASPECTS OF CLINICAL INVESTIGATIONS UNDER THE MDR.....</b>	<b>174</b>
<b>3.4.</b>	<b>Clinical Development Stage.....</b>	<b>187</b>
3.4.1.	Pre-Market Clinical Investigations.....	188
3.4.2.	Confirmatory/Pivotal Clinical Investigations, .....	190
3.4.3.	Post-Market Clinical Investigations .....	190
3.4.4.	Clinical Development Strategy.....	191
<b>3.5.</b>	<b>Clinical Investigation Plan (CIP) .....</b>	<b>192</b>
3.5.1.	Formal Aspects of the Clinical Investigation Plan (CIP) .....	192
3.5.2.	Objective(s) of Clinical Investigation .....	192
3.5.3.	Endpoint(s) of Clinical Investigations.....	193
<b>3.6.</b>	<b>Statistical Considerations .....</b>	<b>197</b>
3.6.1.	RANDOMISATION .....	197
3.6.2.	STATISTICAL METHODS.....	197
3.6.3.	MULTIPLE TESTING .....	198
3.6.4.	SAMPLE SIZE CALCULATION.....	200
<b>3.7.</b>	<b>Investigators' Brochure (IB).....</b>	<b>202</b>
<b>3.8.</b>	<b>Clinical Investigation Report (CIR) and its Summary Report.....</b>	<b>205</b>
<b>3.9.</b>	<b>Informed Consent and Special Protection of Vulnerable Subjects/Populations .....</b>	<b>208</b>
3.9.1.	General considerations on Basic Ethical Principles .....	208
3.9.2.	Informed Consent.....	208
3.9.2.1.	The Legal Basis for Informed Consent .....	209
3.9.2.1.1.	Definition .....	209
3.9.2.1.2.	The General Requirement to Obtain Informed Consent .....	209
3.9.2.1.3.	Specific Conditions for Informed Consent for Clinical Investigations on Minors .....	210
3.9.2.2.	Process of Obtaining Informed Consent.....	211
3.9.2.3.	Special Circumstances for Informed Consent .....	212
3.9.2.4.	Information to be Provided to the Subject.....	214
3.9.2.5.	Informed Consent Signature Form .....	217
3.9.3.	Clinical investigations in Specific Vulnerable Subjects/Populations and Situations .....	218
3.9.3.1.	Clinical investigations on incapacitated subjects .....	218

- 3.9.3.2. Clinical Investigations on Minors.....219
- 3.9.3.3. Clinical investigations Involving Pregnant and Breast-Feeding Women .....221
- 3.9.3.4. Additional Vulnerable Groups in Clinical Investigations Considered by National Measures .....221
- 3.9.3.5. Clinical investigations in Emergency Situations .....222
- 3.9.3.6. Damage Compensation .....223

**4. MONITORING OF CLINICAL INVESTIGATIONS OF MEDICAL DEVICES FOR HUMAN SUBJECTS 224**

- 4.1. Sources.....224**
- 4.2. General Requirements for Monitoring .....226**
- 4.3. The Monitor.....226**
- 4.4. Assessment of the Investigation Site .....227**
- 4.5. Initiation of the Investigation Site.....228**
- 4.6. Routine Monitoring Visits.....230**
- 4.7. Close-Out Visits.....233**
- 4.8. Monitoring Reports.....234**
- 4.9. Supporting Documents.....234**
  - 4.9.1. Monitoring Plan.....234
  - 4.9.2. Documents Related to Informed Consent (see chapter 3.9.2).....235
  - 4.9.3. Site Evaluation Visit Report .....235
  - 4.9.4. Site Initiation Visit Report .....237
  - 4.9.5. Monitoring Visit Report.....239
  - 4.9.6. Site Closure Report.....240
  - 4.9.7. Document for Centre Release .....242
  - 4.9.8. Site Level: Medical Device Accountability Log .....243
  - 4.9.9. Subject Level: Medical Device Accountability Log .....244
  - 4.9.10. Temperature Log .....245
  - 4.9.11. Storage Temperature Excursion Form .....246
  - 4.9.12. Site Training Documentation Form .....247
  - 4.9.13. Site Visit Log .....248

4.9.14. Delegation of Investigation Site Team Responsibility  
Log..... 249

4.9.15. Biological Sample Log ..... 250

**LIST OF FIGURES** **251**

**LIST OF TABLES** **252**

**LIST OF BOXES** **252**

**LIST OF FORMS** **253**

**INDEX** **254**